AI Chat Paper
Note: Please note that the following content is generated by AMiner AI. SciOpen does not take any responsibility related to this content.
{{lang === 'zh_CN' ? '文章概述' : 'Summary'}}
{{lang === 'en_US' ? '中' : 'Eng'}}
Chat more with AI
Powered by AMiner. Clicking this button will take you away from SciOpen.
Home Journal of Traditional Chinese Medical Sciences Article
PDF (370.7 KB)
Cite
EndNote(RIS) BibTeX
Collect
AI Chat Paper
Show Outline
Outline
Show full outline
Hide outline
Outline
Show full outline
Hide outline
Review | Open Access

Clinical applications and pharmacological research progress of Lianhua Qingwen capsules/granules

Zhenhua Jiaa,b,c,d( ), Yiling Wub,c,d
Hebei Yiling Hospital, Shijiazhuang, 050091, China
State Key Laboratory of Collateral Disease Research and Innovative Chinese Medicine Medicines, Key Laboratory of National Administration of Traditional Chinese Medicine, Shijiazhuang, 050035, China
Key Laboratory of National Administration of Traditional Chinese Medicine (Cardiovascular & Cerebrovascular Collateral Disease), Shijiazhuang, 050035, China
Hebei Academy of Integrated Traditional Chinese and Western Medicine, Shijiazhuang, 050035, China

Peer review under responsibility of Beijing University of Chinese Medicine.

Show Author Information

Abstract

Lianhua Qingwen capsule/granule is an innovative Chinese medicine developed under the guidance of the traditional Chinese medicine (TCM) collateral disease theory. It has the effect of "clearing heat and removing toxin, ventilating the lungs and discharging heat". In 2003, it was approved as a new drug by the China National Medical Products Administration, through expedited approval during severe acute respiratory syndrome, and now, it has become a representative proprietary Chinese medicine for the treatment of infectious diseases of the respiratory system. Pharmacodynamic studies have revealed that Lianhua Qingwen has broad-spectrum antiviral, antibacterial and anti-inflammatory, antipyretic, cough-relieving, and immunoregulation effects. Clinically it has been used in the treatment of communicable and infectious respiratory diseases such as Coronavirus Disease 2019, influenza, colds, pulmonary infections, etc. and has achieved remarkable curative effects, showing the important clinical guidance of the TCM collateral disease theory.

Keywords

COVID-19InfluenzaTraditional Chinese medicinePneumoniaCollateral disease theoryLianhua Qingwen

References

1
World Health Organization. Coronavirus disease (COVID-2019) situation reports; 2020. https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports. Accessed January 1, 2020. Accessed.
2

Çelik I, Saatçi E, Eyüboğlu AF. Emerging and reemerging respiratory viral infections up to Covid-19. Turk J Med Sci. 2020;50(SI-1): 557-562.
Crossref Google Scholar
3

Paget J, Spreeuwenberg P, Charu V, et al. Global mortality associated with seasonal influenza epidemics: new burden estimates and predictors from the GLaMOR Project. J Glob Health. 2019;9(2): 020421.
Crossref Google Scholar
4

Wu YL. Synopsis of collateral disease. Chin J Difficult Complicated Cases. 2004;3(1): 37-39 [Chinese].
Google Scholar
5

Wu YL. Three milestones in the formation and development of collateral disease theory (1). Chin J Difficult Complicated Cases. 2004;3(2): 89-91 [Chinese].
Google Scholar
6

Wu YL. Three milestones in the formation and development of collateral disease theory (2). Chin J Difficult Complicated Cases. 2004;3(3): 149-151 [Chinese].
Google Scholar
7

Wu YL. The construction of collateral disease theory system. Chin J Difficult Complicated Cases. 2005;4(6): 349-350 [Chinese].
Google Scholar
8

Wu YL. TCM collateral disease theory and three-dimensional network system. J Tradit Chin Med. 2003;44(6): 407-409 [Chinese].
Google Scholar
9
Li ZG, Liu XR. Trans. Baibing Shisheng: the occurrence of all diseases. In: Yang MZ, ed. Yellow Emperor's Canon of Medicine · Spiritual Pivot. Xi'an, China: Xi'an World Publishing Corporation; 2005: 787-789.
10

Jia ZH. Discussion about guidance of diagnosis and treatment of COVID-19 by Luobing Theory. Chin J Exper Tradit Med Formul. 2020;26(12): 18-22 [Chinese].
Google Scholar
11

Jia ZH, Wu YL. The research of exogenous febrile disease guided by the collateral disease theory. Glob Tradit Chin Med. 2010;3(1): 26-28 [Chinese].
Google Scholar
12

Zhu SY, Li XY, Wei YL, Yang PY, Qin ED. Inhibitory effects of three prescriptions of traditional Chinese medicine on SARS-associated coronaviruses in vitro. Lett Biotechnol. 2003;14(5): 390-392 [Chinese].
Google Scholar
13

Li RF, Hou YL, Huang JC, et al. Lianhuaqingwen exerts anti-viral and anti-inflammatory activity against novel coronavirus (SARS-CoV-2). Pharmacol Res. 2020;156: 104761.
Crossref Google Scholar
14

Duan ZP, Jia ZH, Zhang J, et al. Natural herbal medicine Lianhuaqingwen capsule anti-influenza A (H1N1) trial: a randomized, double blind, positive controlled clinical trial. Chin Med J (Engl). 2011;124(18): 2925-2933.
Google Scholar
15

Mo HY, Ke CW, Zheng JP, Zhong NS. Anti-viral effects of Lianhua Qingwen capsule against influenza A virus in vitro. Tradit Chin Drug Res Clin Pharmacol. 2007;18(1): 5-9 [Chinese].
Google Scholar
16

Ding YW, Zeng LJ, Li RF, et al. The Chinese prescription lianhuaqingwen capsule exerts anti-influenza activity through the inhibition of viral propagation and impacts immune function. BMC Compl Alternative Med. 2017;17(1): 130.
Crossref Google Scholar
17
Liu XY. Preliminary Study of Lianhua Qingwen Capsule on Virus Inhibition [master's Thesis]. Kunming, China: Kunming University of Science and Technology; 2015 [Chinese].
18

Liu Z, Shi FZ, Yang ZQ. Antiviral activity of Lianhua Qingwen capsules against coxsackie B4 in vitro. J South-Central Univ Nationalities Nat Sci Ed. 2012;31(1): 20-24 [Chinese].
Google Scholar
19

Ding YW, Zeng LJ, Li RF, et al. Pharmacological action of Lianhua Qingwen granules on BALB/c mice infected with respiratory syncytial virus. J Guangzhou Univ Tradit Chin Med. 2016;33(4): 541-544 [Chinese].
Google Scholar
20

Shi LK, Wang Y, Dong X, et al. In vitro antibacterial experiment of Lianhua Qingwen capsules combined with meropenem against drug-resistant strains. Chin J Nosocomiol. 2019;29(8): 1172-1175 [Chinese].
Google Scholar
21
Wang YZ. Inhibitory Effect of Genetic Mechanism of Lianhua Qingwen Capsule on Respiratory Infection Related Bacterial Biofilm [master's Thesis]. Changchun, China: Jilin University; 2014 [Chinese].
22

Lei HT, Liu MY, Ouyang JF, et al. Study on Lianhua Qingwen capsule resisting Staphylococcus aureus biofilm. Chin J Exper Tradit Med Formul. 2013;19(22): 161-164 [Chinese].
Google Scholar
23

Hu K, Guan WJ, Bi Y, et al. Efficacy and safety of Lianhuaqingwen capsules, a repurposed Chinese herb, in patients with coronavirus disease 2019: a multicenter, prospective, randomized controlled trial. Phytomedicine. 2021;85: 153242.
Crossref Google Scholar
24

Cheng DZ, Wang WJ, Li Y, Wu XD, Zhou B, Song QY. Analysis of the efficacy of Chinese medicine Lianhua Qingwen in 51 patients with COVID-19: a multi-center retrospective study. Tianjin J Tradit Chin Med. 2020;37(5): 509-516 [Chinese].
Google Scholar
25

Yao KT, Liu MY, Li X, Huang JH, Cai HB. Retrospective clinical analysis on treatment of novel coronavirus-infected pneumonia with traditional Chinese medicine Lianhua Qingwen. Chin J Exper Tradit Med Formul. 2020;26(11): 8-12 [Chinese].
Google Scholar
26

Wang SX, Li MY, Chen XL, Ma MY, Hu JH. Clinical efficacy of Lianhua Qingwen integrated with Western medicine on COVID-19 by meta-analysis. Chin Tradit Herb Drugs. 2020;51(14): 3763-3769 [Chinese].
Google Scholar
27

Cardone M, Yano M, Rosenberg AS, Puig M. Lessons learned to date on COVID-19 hyperinflammatory syndrome: considerations for interventions to mitigate SARS-CoV-2 viral infection and detrimental hyperinflammation. Front Immunol. 2020;11: 1131.
Crossref Google Scholar
28
Ye CH, Gao MN, Lin WQ, Yu KQ, Li P, Chen GH. Theoretical study of the antiNCP molecular mechanism of traditional Chinese medicine Lianhua-Qingwen Formula (LQF). ChemRxiv; 2020. https://chemrxiv.org/articles/preprint/Theoretical_Study_of_the_anti-NCP_Molecular_Mechanism_of_Traditional_Chinese_Medicine_Lianhua-Qingwen_Formula_LQF_/12016236/1. Accessed March 21, 2020. Accessed.
Crossref
29

Wang L, Yang ZH, Zhang HR, et al. Study on the network pharmacology and preliminary evidence of Lianhua Qingwen in the treatment of Novel Coronavirus (2019-nCoV) pneumonia. J Chin Med Mater. 2020;43(3): 772-778 [Chinese].
Google Scholar
30

Ling XY, Tao JL, Sun X, Yuan B. Exploring material basis and mechanism of Lianhua Qingwen Prescription against coronavirus based on network pharmacology. J Chin Med Mater. 2020;51(7): 1723-1730 [Chinese].
Google Scholar
31

Wang FC, Shen BX, He CY, Zhao WC, Nie SL. Clinical efficacy and mechanism of Lianhua Qingwen granule on COVID-19 based on network pharmacology research. Pharmacol Clin Chin Mater Med. 2020;36(2): 93-101 [Chinese].
Google Scholar
32

Chen XF, Wu YL, Chen C, et al. Identifying potential anti-COVID-19 pharmacological components of traditional Chinese medicine Lianhuaqingwen capsule based on human exposure and ACE2 biochromatography screening. Acta Pharm Sin B. 2021;11(1): 222-236.
Crossref Google Scholar
33

Liu GX, Zhang YX, Yang JQ, Gao ZQ, Meng YC. The randomized controlled clinical study of Lianhuaqingwen capsule in treating A/H1N1 influenza. Chin J Difficult Complicated Cases. 2010;9(1): 14-16 [Chinese].
Google Scholar
34

Zhao P, Yang HZ, Lv HY, Wei ZM. Efficacy of Lianhuaqingwen capsule compared with oseltamivir for influenza A virus infection: a meta-analysis of randomized, controlled trials. Alternative Ther Health Med. 2014;20(2): 25-30.
Google Scholar
35

Niu QQ, Chen Y, Liu Y, et al. Efficacy and safety of Lianhua Qingwen capsule for influenza: a systematic review. China J Chin Mater Med. 2017;42(8): 1474-1481 [Chinese].
Google Scholar
36

Zhu SJ, Li SJ, Li WB. Lianhua Qingwen granule combined with oseltamivir phosphate in the treatment of influenza A in children. Chin J Clin Res. 2019;32(8): 1099-1101 [Chinese].
Google Scholar
37

Liu Y, Yang J, Zhao XK, Zhou MY. Clinical analysis of Lianhua Qingwen granule combined with oseltamivir phosphate in the treatment of pediatric influenza A. J Chin Prescript Drug. 2020;18(11): 128-130 [Chinese].
Crossref Google Scholar
38
The Chinese Academy of Military Medical Sciences and Beijing Ditan Hospital confirmed that the anti-H1N1 influenza virus: a major breakthrough in the traditional Chinese medicine Lianhua Qingwen capsules. J Chin Prescript Drug. 2009;9(90): 41 [Chinese].
39

Mo HY, Yang ZF, Zheng JP, Mo ZY, Zeng YM, Xiao ZL. Experimental study of Lianhua Qingwen capsule in preventing and treating influenza virus FM1 infection in mice. J Chin Med Mater. 2008;31(8): 1230-1233 [Chinese].
Google Scholar
40

Wei M, Song HX, Zhou H. Effect of Lianhuaqingwen capsule on acute upper respiratory infection and their impact on IFN-γ. Chin J Difficult Complicated Cases. 2014;13(4): 345-348 [Chinese].
Google Scholar
41

Zhao MJ, Zhao XQ, Zhao W. Clinical effects of Lianhua Qingwen capsule in the treatment of acute respiratory infections. Chin J Nosocomiol. 2015;25(4): 839-841 [Chinese].
Google Scholar
42
Liu HK, Hou L, Huang HL, Han T. Meta-analysis of the clinical efficacy of Lianhua Qingwen capsule in the treatment of acute upper respiratory infection. Paper Presented at: 15th Annual Conference of Chinese Medicine Prescriptions of Chinese Society of Chinese Medicine; May 1, 2015; Xianyang, China [Chinese].
43

Wang SH, Liu JF, Zhang YL, Dong Z. Systematic review of the efficacy and safety of Lianhua Qingwen capsules in the treatment of viral influenza. China J Chin Mater Med. 2019;44(7): 1503-1508 [Chinese].
Google Scholar
44

Li B, Sun YS, Li HY. Efficacy of Lianhua Qingwen granule on children with viral upper respiratory infection and fever and its impact on the expressions of serum amyloid A and inflammatory factors. J Chin Med Mater. 2020;43(6): 1490-1493 [Chinese].
Google Scholar
45

Jain N, Lodha R, Kabra SK. Upper respiratory tract infections. Indian J Pediatr. 2001;68(12): 1135-1138.
Crossref Google Scholar
46

Jiang X, Wang ZP, Yu T, et al. Clinical observation of Lianhua Qingwen capsule in the treatment of community-acquired pneumonia. Chin J Clin Rational Drug Use. 2014;7(4A): 59-60 [Chinese].
Google Scholar
47

Hu XQ, Wan Y, Lu Q, et al. Clinical study of Lianhua Qingwen capsules combined with cefuroxime in treatment of community acquired pneumonia. Drugs Clin. 2018;33(12): 3216-3220 [Chinese].
Google Scholar
48

Lu ZJ, Wu LY, Mou YY, et al. Meta-analysis and systematic review of efficacy and safety of Lianhua Qingwen in adjuvant treatment of adult pneumonia. China J Chin Mater Med. 2021;46(4): 1000-1009 [Chinese].
Google Scholar
49

Zhou JG, Yang M, Cao HT, Hua C. The clinical application of detection of lymphocyte subsets. 321 Military Med J Southeast China. 2015;17(3): 298-300 [Chinese].
Google Scholar
50

Chen Y, Han CQ, Zhao FL, Fu HL, Xi YF. Effects of Lianhua Qingwen granules combined with azithromycin on children with mycoplasma pneumoniae pneumonia. World Chin Med. 2020;15(1): 76-80 [Chinese].
Crossref Google Scholar
51
Respiratory Society of Chinese Medical Association. Guideline on diagnosis and treatment of community acquired-pneumonia in Chinese adults (2016 Edition). Chin J Tuberc Respir Dis. 2016;39(4): 253-279 [Chinese].
52

Zhang Y, Cheng C, Su JC, et al. Preparation of rat model of acute lung injury and comparison of injury at different periods. Acta Lab Anim Sci Sin. 2021;29(1): 27-34 [Chinese].
Google Scholar
53

Cui WW, Jin X, Zhang YF, Chang LP, Wang HT. Effects of Lianhua Qingwen capsules on IKK/IκB/NF-κB signaling pathway in mouse with LPS-induced acute lung injury. Chin Tradit Patent Med. 2015;37(5): 953-958 [Chinese].
Google Scholar
54

Cui WW, Jin X, Zhang YF, Wang HT, Mi Y, He QL. Effects of Lianhuaqingwen capsules on inflammatory cytokines and junction protein expression in mice with acute lung injury induced by lipopolysaccharides. Chin J Pharmacol Toxicol. 2015;29(2): 213-219 [Chinese].
Google Scholar
55

Xu N, Ping F, Xu X, Zhuge MN, Zhang FR, Han SZ. Antagonistic effects of Lianhuaqingwen on rats' pulmonary inflammatory injury induced by airborne fine particulate matters. Chin General Pract. 2015;18(27): 3355-3359 [Chinese].
Google Scholar
56

Tang SW, Zhang YF, Liu KJ, Xu DF, Wang HR, Li ZJ. Effects of Lianhua Qingwen capsule on lung tissue injury and expression of inflammatory cytokines in mice exposed to automobile exhaust. Chin J Exper Tradit Med Formul. 2015;21(13): 139-143 [Chinese].
Google Scholar
57

Bai R, Yang C. Effects of thymopentin combined with Lianhua Qingwen capsule on AECOPD patients and its influence on immune function. Lab Med Clin. 2018;15(5): 592-595 [Chinese].
Google Scholar
58

Tian JX, Chen XX, Wang JP. Effect of Lianhua Qingwen capsule combined with vitamin D on CAT, mMRC score and Th17/Treg cytokine balance in the treatment of chronic obstructive pulmonary disease. Modern J Integr Tradit Chin West Med. 2018;27(32): 3554-3557 [Chinese].
Google Scholar
59

Dong L, Xia JW, Gong Y, Chen XD. Clinical effect of Lianhua Qingwen capsules on patients with acute exacerbation of chronic obstructive pulmonary disease and its mechanism. Chin Tradit Patent Med. 2014;36(5): 926-929 [Chinese].
Crossref Google Scholar
60

Wei H. Clinical study of Lianhua Qingwen capsules combined with terbutaline and budesonide in treatment of acute exacerbation of chronic obstructive pulmonary disease. Drugs Clin. 2016;31(7): 973-977 [Chinese].
Google Scholar
61
Zhang XC, Liu XH. In: Records of Chinese Medicine with Reference to Western Medicine. Beijing, China: People's Medical Publishing House; 2006 [Chinese].
62

Guo H, Zhang QH, Yang J, Gong JN, Zhao YS, Zhou XP. Effect of Lianhua Qingwen capsule on immunity of mice infected with flu virus. J Nanjing Tradit Chin Med Univ. 2007;23(2): 106-108 [Chinese].
Google Scholar
63

Wang YX, Zhang KY, Huang JH, Han SL, Zhao JH, Xu ZJ. Clinical drug safety of Lianhuaqingwen preparation: a systematic evaluation. Eval Analys Drug Use Hospitals Chin. 2013;13(8): 676-681 [Chinese].
Google Scholar
64

Shi LX, Chen S, Zhou J, Liu LQ. Analysis of 69 adverse reaction reports of Lianhua Qingwen preparation. Strait Pharmaceut J. 2020;32(12): 263-265 [Chinese].
Google Scholar
65

Hu P. Side effects of rhubarb should not be ignored. Capital Med. 2002;4: 42 [Chinese].
Google Scholar
66

Zhao XY, Liang Y, Kong DW, Zhang L, Du GH. The historical cognition and evaluation of Cyrtomium fortunei. Pharmacol Clin Chin Mater Med. 2019;35(2): 156-159 [Chinese].
Google Scholar
Journal of Traditional Chinese Medical Sciences
Volume 8 Issue 2,
April 2021
Pages 101-109
DOI: 10.1016/j.jtcms.2021.05.001
Cite this article:
Jia Z, Wu Y. Clinical applications and pharmacological research progress of Lianhua Qingwen capsules/granules. Journal of Traditional Chinese Medical Sciences, 2021, 8(2): 101-109. https://doi.org/10.1016/j.jtcms.2021.05.001

461

Views

14

Downloads

2

Crossref

7

Scopus

Altmetrics
Received: 09 April 2021
Revised: 06 May 2021
Accepted: 06 May 2021
Published: 10 May 2021
© 2021 Beijing University of Chinese Medicine.

This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Return